Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ImmuKnow ATP-guided minimization of immunosuppressant dose after liver transplantation
ChiCTR-ONRC-11001688Phase 3Completed
- Sponsor
- Renji Hospital
- Start
- Jan 2011
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of tacrolimus in liver transplant (2 arms), sponsored by Renji Hospital. Primary endpoint: Incidence of biopsy-proven acute rejection or clinical acute rejection at trial endpoint. Started Jan 2011; status: completed.
02
Drugs
tacrolimus
03
Conditions
liver transplant
Beyond the preview
Go deeper on ChiCTR-ONRC-11001688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-ONRC-11001688.